anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
FIELD: medicine.SUBSTANCE: method involves thermal and mechanical exposure on lower abdomen and lumbosacral spine taking into account the localisation and prevalence of the adhesive process in the small pelvis, and vaginal administration of a therapeutic solution. The 10-minute thermal exposure represents placing thermocompressors S = 980 cmeach, heated to 48-50°C onto the lower abdomen and lumbosacral spine. That is followed by manual gynaecological massage to eliminate right- or left-side adhesive process by performing the following techniques: second and third fingers of right hand are inserted into vagina and moved to right or left vaginal wall respectively; fingers of left hand are placed above a projection of appendages on the right or on the left respectively on an anterior abdominal wall; fingers of right hand are brought apart with executing stretching motions between uterus and appendages and massaging circular motions with fingers of left hand from above. Fingers of right and left hands execute massaging motions so as trying to place them above each other; rotational directed motions are executed to move uterus to the left or to the right respectively. The adhesive process between intestine and posterior wall of uterus is eliminated by the following techniques: fingers of right hand are inserted into vagina behind neck of uterus into posterior vaginal vault to lift uterus slightly; fingers of left hand are brought behind uterus from the side of abdominal wall; massage is performed with circular motions, whereas fingers of right and left hands are connected together. A saltosalpinx is eliminated with evacuating fluid from uterine tube into uterus and further into vagina by massaging from fimbrial to uterine end of uterus. The manual gynaecological massage is followed by vaginal administration of the therapeutic solution in the form of &#34;Sakskoye Lake&#34; sulphide silt therapeutic mud heated to 48-50°C in an amount of 90 ml to be removed 20-30 min later.EFFECT: method provides the non-invasive painless elimination of the adhesive process in the woman&#39;s small pelvis with the stable therapeutic effect.4 ex
PROBLEM TO BE SOLVED: To obtain a pharmaceutical composition for prevention or treatment of gastric ulcer, capable of being readily administered without manifesting side effect such as sleepiness and drug hypersensitivity reaction by including an extract of a chicken and/or an extract of an oyster. SOLUTION: The objective pharmaceutical composition contains (A) an extract of a chicken and/or (B) an extract of an oyster. Blood is removed from a body part of the Japanese produced chicken so-called &#39;aboriginal hen&#39;, and the body part with the removed blood is pulverized. The pulverized body part is extracted by a double boiled method to provide (i) a chicken extract. An oil component ad cholesterol are removed from the chicken extract (i) and the resultant chicken extract (i) is condensed to provide (ii) a condensed chicken extract. Sterilized water is added to the condensed chicken extract (ii), and sugar content is regulated. The sugar content-regulated product is freeze-dried to provide (iii) a chicken extract powder. The components (i), (ii) and (iii) can be used as the component A.  (iv) A water-soluble extract obtained by treating Crassostrea gigas with an enzyme is condensed to provide (v) a condensed extract, and the condensed extract (v) is dried to provide (vi) an oyster extract powder. The components (iv), (v) and (vi) can be used as the component B.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new derivative for reducing adverse effects of a pharmaceutical compound having kinase inhibitory actions and to provide a pharmaceutical composition comprising the derivative.  &lt;P&gt;SOLUTION: A phosphorus-substituted kinase inhibitory compound is obtained by introducing a phosphonic acid ester into a pharmaceutical having the kinase inhibitory actions (e.g. gefitinib, imatinib, erlotinib, vatalanib or staurosporine). The pharmaceutical composition comprising the compound and a therapeutic method are provided. Thereby, a phosphonate-containing molecule at a high concentration can be achieved in a target cell and the compound can be applied to various therapeutic formulations and treatments (various kinds of tumors, leukemias, inflammatory diseases, psoriases, transplant rejections, etc.).  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide methods and reagents for inducing active immunity in animals.  &lt;P&gt;SOLUTION: Recombinant herpesviruses having foreign DNA can induce active immunity to the herpesvirus. The source of the foreign DNA is provided. Variant herpesviruses have portions of their genome deleted. In the UL54.5 open reading frame of avian herpesviruses or the UL43 open reading frame of Marek&#39;s disease virus, foreign DNA is introduced to recombinant herpesviruses, or a part of their genome is deleted from the recombinant herpesviruses.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain a Maillard reaction suppressor, capable of exhibiting Maillard reaction-inhibiting activity and having high safety by compounding a kind of cyclic α-hydroxyketone compound. SOLUTION: This Maillard reaction suppressor contains a compound of the formula [X is O, C(O) or CH=CH; R&lt;1&gt; to R&lt;3&gt; are each H, OH, a 1-3C hydroxyalkyl or a 1-3C alkyl], concretely at least one kind selected from a group consisting of maltol, tropolone, tetrahydroxy-1,4benzoquinone and 2,5- dihydroxy-1,4-benzoquinone as an active component. The Maillard reaction suppressor is useful for the beautification of the skin, and the prevention and prophylaxis of the senile change of the skin. Further, the suppressor is useful for the treatment and prophylaxis of arteriosclerosis, cataract, etc., attributable to various kinds of diabetic complications and senile changes. The suppressor can be formulated into an oral or parenteral preparation. Furthermore, the suppressor can be used as a component of a cosmetic such as a cream, a milky lotion or a lotion, a food or a food additive.
PROBLEM TO BE SOLVED: To obtain a homogeneous cosmetic composition for skin makeup, capable of providing the translucent makeup with excellent opacity and a quite natural appearance, when used for the skin makeup by including specific powder fractions. SOLUTION: This cosmetic composition for skin makeup contains one or more powder fractions dispersed in a binder comprising an emulsion containing a fatty oil phase and a water phase. The powder fraction has a particle size of 0.1-100 μm and a relative density of D, and further satisfies specified requirements as to a particle concentration per unit volume of the composition and a filler content.  The particle concentration per unit volume of the composition, referred to as C and defined by the equation: C=VCT/(VCT+VG) (VCT is a volume of all of the powder fractions; VG is a volume of non-volatile oil in the fatty oil phase of the binder, which is calculated by subtracting the volume of volatile oil from the total volume of fatty oil phase containing all of the oil-soluble components), is not less than a critical particle concentration C* (according to ASTM specifications D 281-84). The filler content F, defined by the equation: F(%) = 100 × (weight of the powder fractions excluding pigments)÷(total weight of the composition)], is in a range of from F0 to 1.8×F0. F0 is 10, when D&lt;=0.1. F0 is represented by the equation: (60×D)+4, when 0.1&lt;D&lt;=0.6. F0 is 40, when D&gt;0.6.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a novel peptide capable of enhancing immune response activity in a patient having such a risk that the patient may be attacked by a MAGE related tumor, such as a melanoma.  &lt;P&gt;SOLUTION: A human MAGE-1 protein and the peptide are provided, respectively, wherein the peptide is derived from a region consisting of 58 amino acids at a C-terminal of an MAGE-1 antigen. A DNA vector encoding the MAGE-1 protein is transformed into a host, then the MAGE-1 protein is expressed and recovered. The peptide and a vaccine composition are each administered for the purpose of inducing cytotoxic T lymphocyte (CTL) response effective for a MAGE supporting tumor. The peptide is administered to a patient of 70 kg in an amount of about 1.0 μg to about 500 μg as an general range, then the administered amount is controlled according to response and state of the patient. A pharmacological composition for therapeutic treatment is used parenterally, locally, perorally or topically, and is preferably used, for example, intravenously, hypodermically or intramuscularly.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to ophthalmology and can be applied in treatment of progressing keratoconus at its initial stage. Method consists in injection introduction into perylimbal zone of dispersed biomaterial Alloplant. Alloplant is preliminarily diluted in physiological solution in ratio 30 mg of biomaterial per 0.5-1.5 ml of physiological solution with addition of 0.5 ml of dexamethasone. Injections are made under conjunctiva and Tennon&#39;s capsule in 4-6 points around limb in each eye 1 time per 6-12 months. ^ EFFECT: method makes it possible to increase efficiency of keratoconus treatment without risk of trauma and complications. ^ 1 ex
PURPOSE:To provide the subject therapeutic agent composed of a giant molecular compound in which radioactive metal ions are bonded to a biodegradable hydrophilic polymer containing monomer units having an amino group, a hydroxyl group, COOH group, etc., and exhibiting suitable retention and rapid discharge to the outside of the body. CONSTITUTION:This is a pharmaceutically permissible radiotherapeutic agent for local administration, capable of gelation at physiological pH and temperature, exhibiting suitable retention and rapid discharge to the outside of the body in combination, free from a problem related to its production and suppliable at low cost. Production of this agent is carried out by chemically bonding one or more kinds of radioactive metal ions (e.g. yttrium 90 ion) through a complexing agent (e.g. diethylenetriaminepentaacetic acid) to a biodegradable hydrophilic polymer composed of a polysaccharide containing hydrophilic repeating monomer units having an amino group, a hydroxyl group, a carboxyl group or their derivative and having 1X10&lt;3&gt; to 1X10&lt;6&gt; average molecular weight, e.g. chitin, chitosan or their derivative.
NEW MATERIAL:A dihydropyrimidine derivative which is tautomers expressed by formulas I and II (R&lt;1&gt; is lower alkyl; R&lt;2&gt; is phenyl, substituted phenyl, furyl or thienyl) and an acid addition salt thereof. EXAMPLE:5-Alkoxycarbonyl-2,6-dimethyl-4-phenyl-dihydropyrimidine. USE:A safe agent, having vasodilator action, and effective for treating a wide variety of cardiovascular diseases, e.g. hypertension, angina pectoris, arrhythmia, etc. and having selectivity for blood vessels. PREPARATION:A tetrahydropyrimidinol derivative expressed by formula III is treated with a dehydrating agent selected from the group consisting of phosphorus oxychloride, alumina, silica gel and acids and if desired an acid suitable to a medicine to afford the compounds expressed by formulas I and II. For example, a method of heat treatment is carried out in case and acid, e.g. p-toluenesulfonic acid, is used as the dehydrating agent.
PROBLEM TO BE SOLVED: To obtain a new derivative, a galactose group-bearing specific triglyceride derivative, capable of giving lipid membrane structural form for the drug delivery system exhibiting specific affinity for cells having a galactose receptor. SOLUTION: This derivative is a new galactose derivative expressed by formula I (R&lt;1&gt; and R&lt;2&gt; are each a 12-30C saturated or unsaturated fatty acid residue; (n) is an integer of 2-50)(e.g. 1,2dipalmitoyl-3-O- glycerinylpolyethylenedioxyethyl-D-galactosyl succinate), being useful for e.g. lipid membrane structural, form for e.g. the drug den-ivery system(DDS) having specific affinity for galactose receptor-bearing cells represented by hepatocyte. This new derivative is obtained by protecting the carboxyl group of 1,2-protected 3-O-glycerinylpolyethylenedioxyethyl succinate of formula II followed by deprotection of the 1,2-sites and acylation, liberation of the terminal carboxylic acid on the 3-site and then binding galactose thereto.
The invention relates to an in vitro method for the analysis of a sample extracted from a mammal in relation to cardiovascular diseases. Said method comprises the following steps: a) the bone marrow precursor cells (BMP) and/or circulation precursor cells (BDP) derived from blood (BDP) are insulated by means of cell specific surface markers, and b) the cardiovascular functionality of the insulated BMP and/or BDP is examined by means of a suitable migration test. The inventive method can be used in the form of a kit in the field of diagnosis and/or prognosis of cardiovascular diseases, can be used to monitor the therapy thereof and/or for the stratification of cell therapy planted with stem cells and progenitor cells in order to increase perfusion of ischaemic tissue and/or for the regeneration of tissue loss (e.g. heart failure). The invention also relates to an in vitro method for the insulation of specific bone marrow precursor cells by means of a suitable migration test. Said BMP and/or BDP can be used in the treatment of cardiovascular diseases, selected from the group comprising stable coronary diseases, acute coronary syndrome, acute myocardial infarction, chronic ischaemic cardiomyopathy (ICMP), dilatative cardiomyopathy (DCM) or other causes of cardiac insufficiency. ® KIPO &amp; WIPO 2007
1457277 Antisera suppressing tissue transplant rejection G .D SEARLE &amp; Co Ltd 31 July 1974 [9 Aug 1973] 37800/73 Heading A5B Antisera useful in tissue typing and in suppressing rejection of tissue transplants are produced by collecting an antierum containing antibodies to the antigens which cause transplant rejection and removing from the antiserum antibodies against serodominant transplantation antigens by selectively absorbing such antibodies on a substrate. The antiserum may be produced by injecting antigenic material from a prospective transplant donor or another individual of similar genetic type into a host. The donor and recipient may be human. The host may be a human or an animal, eg a rodent. Alternatively the antiserurn, may be collected from a multiporous woman of known antigenic profile. The suibstrate may be material containing serodominant transplantation antigens, e.g. red blood cells, platelets or liver cell material..
PURPOSE:To obtain dried root of NANBAN-KARASU-URI (Momordica cochinchinensis) having excellent expectorant activity and free from irritation of pharyngeal mucosa, preventing the decomposition of momordin II, by contacting raw root of NANBAN-KARASU-URI or its cut pieces with an aqueous solution of an acid. CONSTITUTION:A raw root or cut raw root of NANBAN-KARASU-URI is immersed in an aqueous solution of a mineral acid such as sulfuric acid, hydrochloric acid, etc. The pH of the aqueous solution of the acid is &lt;=2.7, preferably &lt;=0.5 and the root is made to contact with the solution at -10-+40 deg.C for 0.5-40hr, preferably at 0-35 deg.C for 1-4hr. The treated root is made to contact with an aqueous solution of a base (e.g. ammonia) to neutralize the acid and is dried to obtain the objective product. The aqueous solution of base has 7.5-12pH and is made to contact with the root at -10-+40 deg.C for 2-40hr.
A folk prescription for treating livestock pleuropneumonia is discloses. According to the folk prescription, a proper amount of cowpea is selected for treating livestock pleuropneumonia. If livestock catch a cold and choke continuously, cowpea can be used for feeding. According to the feeding method, cowpea is better uncooked. Big livestock are fed twice a day, once in the morning and once in the evening, 0.5-1 kg for each time. Small livestock are fed with reduced dosage. In practice, the invention concludes that &#39;&#39;cowpeas are better than tonic in treating damaged lung caused by continuous choke&#39;&#39;.
PURPOSE: To obtain the oil and fat having platelet coagulation-inhibiting, antibacterial and mildew-proofing activities and useful as food, pharmaceutical product, etc., by crushing a scaly bulb of garlic after water is added, adjusting the pH of the liquid, adding an oil and fat to the liquid, and producing and accumulating ajoene by storing under specific conditions. CONSTITUTION: Scaly bulb of 100 pts.wt. of garlic is crushed after 0-100 pts.wt. of water is added. The crushed material is manually squeezed through a nylon filter, etc. After the pH of the obtained juice is adjusted to 5.5-8.5, the juice is added with an oil and fat consisting of fatty acid triglyceride having medium length of chains, etc., those materials are stirred by a homo-mixer, etc., and the obtained mixture is kept at 0-55 deg.C for 3hr to 7 days. An ajoene mixture consisting of Z-ajoene of formula I and E-ajoene of formula II whose molar ratio is &gt;=4 is produced and accumulated in the oil and fat. Thus, the objective ajoene-containing oil and fat is obtained through the process consisting of the contact of the treated garlic with an oil and fat.  The obtained oil and fat has platelet coagulation-inhibiting, antibacterial and mildew- proofing activities and useful as a pharmaceutical product such as a treating agent for thrombosis, arteriosclerosis, hypertension, etc., an antibacterial and mildew-proofing agent, etc., health food, etc.
PURPOSE:To provide a sustained release tablet capable of effectively controlling the dissolution rate of drug component and enabling the use of a hydrophilic drug component or the increase of the concentration of the drug component without increasing the diameter of the tablet. CONSTITUTION:The objective tablet contains hydroxypropylmethylcellulose (HPMC) as a sustained release base component. The HPMC has a particle size distribution to pass at least 95wt.% of the HPMC through a 100 mesh sieve. The substitution degree of methoxyl group is 19-24wt.% and that of hydroxypropoxyl group is 4-12wt.%. The viscosity of 2% aqueous solution of the HPMC at 20 deg.C is preferably &gt;=14,000cP. The content of the HPMC in the sustained release tablet is preferably 5-90wt.%.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a tripeptide having a weak adverse reaction and collagenase inhibition, a fermentation product containing the tripeptide, and excellent food and cosmetic preparations which contain the tripeptide with a weak adverse reaction.  &lt;P&gt;SOLUTION: The tripeptide has collagenase inhibition derived from the skin and fibroblast. The fermentation product is obtained by fermenting royal jelly, green tea powder, and soybean powder with Bacillus natto and contains a tripeptide having collagenase inhibition. The royal jelly may be either homegrown or from China. The green tea powder may be either foreign-grown or homegrown. Further, the soybean powder used can be obtained by drying soybeans, and then pulverizing the dried ones. Furthermore, the food formation and the cosmetic formation have the fermentation product containing the tripeptide having collagenase inhibition as an active ingredient.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
The invention provides a traditional Chinese medicine preparation for treatment of scrofula. The traditional Chinese medicine preparation is prepared from female plant caulis spatholobi roots, male plant caulis spatholobi roots and 60-degree sorghum liquor at certain weight ratios. The above materials are subjected to concentrated decoction, then the decoction is subjected to slag removal and filtration to obtain the traditional Chinese medicine preparation. The traditional Chinese medicine preparation is taken orally, and has special effects in treating scrofula. The traditional Chinese medicine preparation has good curative effects in other tuberculosis. Scrofula is formed because of invasion of mycobacterium tuberculosis through oral cavities, decayed teeth, noses, throats or other pathways. In western medicine, anti-tuberculosis drugs or operative treatments are employed to treat scrofula. In traditional Chinese medicine, scrofula is generally named &#34;luoli&#34;, also named &#34;tanhe&#34;, if scrofula is located in necks, scrofula is usually called &#34;lizijing&#34; and in my place scrofula is usually called &#34;jiuziyang&#34;. Liver qi and phlegm fire stagnate in liver and gallbladder meridians to form scrofula. Scrofula is treated by means of medicines with functions of soothing liver, nourishing blood, dispelling melancholy and reducing phlegm. But no matter traditional Chinese medicine or western medicine, curative effects are not satisfied, and until now no specific medicine comes out. The traditional Chinese medicine preparation makes up for the blank, and scrofula can be cured thoroughly.
In general, this disclosure describes techniques for remotely monitoring the health of an ambulatory patient. As described herein, an ambulatory patient may interact with a monitoring device that is located at the patient&#39;s home. The monitoring device may prompt the patient to provide responses to health-related questions or requests for physiological characteristics and may upload the responses. A health care professional may then use the responses to evaluate the health of the patient. A set of firmware instructions stored on the monitoring device may cause the monitoring device to perform these functions. These firmware instructions remain the same even when the monitoring device downloads new prompts.
A methods for altering expression of a target nucleic acid sequence in a target cell by production of single-stranded cDNA (ss-cDNA) in the target cell in vivo. The target cell is transfected with a cassette comprising a sequence of interest, an inverted tandem repeat, and a primer binding site 3&#39; to the inverted tandem repeat. Transcription of the cassette by the target cell produces an RNA template which is reverse transcribed to produce ss-cDNA of a specified sequence. A reverse transcriptase/RNAse H coding gene may also be transfected into the target cell. The ss-cDNA is modified to remove all flanking vector sequences by taking advantage of the &#34;stem-loop&#34; structure of the ss-cDNA, which forms as a result of the inverted tandem repeat that allows the ss-cDNA to fold back on itself, forming a double stranded DNA stem. The double-stranded stem contains one or more restriction endonuclease recognition sites and the loop, which remains as ssDNA, is comprised of the sequence of interest, which can be any desired nucleotide sequence. This design allows the double-stranded stem of the stem-loop intermediate to be cleaved by the desired corresponding restriction endonuclease(s) and the loop portion, or sequence of interest, is then released as a linearized, single-stranded piece of DNA. This released (or cleaved) ssDNA piece contains minimal, if any, sequence information either upstream 5&#39; or downstream 3&#39; from the double stranded stem. The resulting ssDNA binds to an endogenous target nucleic acid sequence to alter the expression of that sequence for such therapeutic purposes as gene inactivation using duplex or triplex binding of nucleic acids, site-directed mutagenesis, interruption of cellular function by binding to specific cellular proteins, and interfering with RNA splicing functions.
FIELD: chemistry. ^ SUBSTANCE: invention can be used in paint-and-varnish industry. To obtain a composition of metallic pigments, initial metal particles are added to a liquid carrier and the obtained mixture is ground. The liquid carrier is a fatty acid ester R&#39;-COOR in which R&#39; is a saturated or unsaturated aliphatic group containing 9-20 carbon atoms and R is an alkyl containing 1-8 carbon atoms. Paint, ink, plastic and a cosmetic composition containing the obtained metallic pigment composition are disclosed. ^ EFFECT: invention increases covering power and lustre of paint materials. ^ 18 cl, 8 tbl, 4 ex